These substances are related to the DEA’s interest in researching hallucinogenic controlled products for clinical tests and research. The DEA asserts that it wants to support the regulated trials of schedule 1 substances, so increasing the production quota explains why this move is essential. The DEA also wants to research the requirements for manufacturing new drugs and the kind of impact marijuana has on the body. These steps are taken to work towards the Food and Drug Administration’s possibilities to approve a new drug.
Germany has received nearly 900 applications for cannabis cultivation associations, but only just over half…
A Senate stopgap funding bill would delay the federal prohibition on most hemp-derived THC products…
He smokes in boardrooms, but he’s still on that underground frequency. This content originally appeared…
Fox News opinion ran a piece recently from Scott Chipman, vice president of Americans Against…
For our 50th anniversary, we handed the plant to the artists making its most striking…
Corporate valuation increased in 21 of the 38 states studied following medical marijuana legalization. Gross…